TY - JOUR
T1 - Theory and strategy for Pneumococcal vaccines in the elderly
AU - Namkoong, Ho
AU - Ishii, Makoto
AU - Funatsu, Yohei
AU - Kimizuka, Yoshifumi
AU - Yagi, Kazuma
AU - Asami, Takahiro
AU - Asakura, Takanori
AU - Suzuki, Shoji
AU - Kamo, Testuro
AU - Fujiwara, Hiroshi
AU - Tasaka, Sadatomo
AU - Betsuyaku, Tomoko
AU - Hasegawa, Naoki
N1 - Publisher Copyright:
© 2016, © Ho Namkoong, Makoto Ishii, Yohei Funatsu, Yoshifumi Kimizuka, Kazuma Yagi, Takahiro Asami, Takanori Asakura, Shoji Suzuki, Testuro Kamo, Hiroshi Fujiwara, Sadatomo Tasaka, Tomoko Betsuyaku, and Naoki Hasegawa.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.
AB - Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.
KW - aging
KW - elderly
KW - pneumococcal conjugate vaccine
KW - pneumococcal diseases
KW - pneumococcal polysaccharide vaccine
KW - pneumococcal vaccines
KW - senescence
UR - http://www.scopus.com/inward/record.url?scp=84960957895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960957895&partnerID=8YFLogxK
U2 - 10.1080/21645515.2015.1075678
DO - 10.1080/21645515.2015.1075678
M3 - Article
C2 - 26406267
AN - SCOPUS:84960957895
SN - 2164-5515
VL - 12
SP - 336
EP - 343
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 2
ER -
